116574-72-2

Basic information

• Product Name: 3-(METHOXYMETHYL)PIPERIDINE
• Synonyms: CHEMBRDG-BB 4002971;3-(METHOXYMETHYL)PIPERIDINE;ASDI-INTER 500020499;OTAVA-BB 1147286;piperidine, 3-(methoxymethyl)-;3-(methoxymethyl)piperidine(SALTDATA: HCl)
• CAS NO: 116574-72-2
• Molecular Formula: C₇H₁₅NO
• Molecular Weight: 129.2
• Mol File: 116574-72-2.mol

Chemical Properties

• Boiling Point: 168℃
• Flash Point: 60℃
• Appearance: /
• Density: 0.882
• Vapor Pressure: 1.67mmHg at 25°C
• Refractive Index: 1.425
• CAS DataBase Reference: 3-(METHOXYMETHYL)PIPERIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(METHOXYMETHYL)PIPERIDINE(116574-72-2)
• EPA Substance Registry System: 3-(METHOXYMETHYL)PIPERIDINE(116574-72-2)

Safety Data

• Hazard Codes: Xn
• Statements: 22
• HazardClass: IRRITANT
• Hazardous Substances Data: 116574-72-2(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Research and Development:
3-(Methoxymethyl)piperidine is used as a key intermediate in the synthesis of various pharmaceuticals, particularly for the development of drugs targeting central nervous system disorders and analgesics. Its unique structure allows for the creation of molecules with specific therapeutic properties, enhancing the treatment options for patients.
Used in Organic Synthesis:
In the field of organic synthesis, 3-(methoxymethyl)piperidine is utilized as a building block for the creation of complex organic molecules. Its reactivity and functional group compatibility make it a valuable component in the synthesis of a wide range of compounds.
Used in Specialty Chemicals Production:
3-(Methoxymethyl)piperidine is employed as a precursor in the manufacture of specialty chemicals, where its unique properties contribute to the development of high-performance materials with specific applications.
Used in Agrochemicals Production:
In the agrochemicals industry, 3-(methoxymethyl)piperidine is used as a starting material for the synthesis of bioactive compounds with potential applications in crop protection and pest management, contributing to the development of effective and environmentally friendly solutions for agriculture.

InChI:InChI=1/C7H15NO/c1-9-6-7-3-2-4-8-5-7/h7-8H,2-6H2,1H3

Upstream product

• 116574-71-1 (±)-tert-butyl 3-(hydroxymethyl)piperidine-1-carboxylate 
• 868065-26-3 t-butyl 3-(methoxymethyl)piperidine-1-carboxylate 

Relevant articles and documents

Ruthenium-catalyzed α-(hetero)arylation of saturated cyclic amines: Reaction scope and mechanism

Transition-metal-catalyzed sp3 C-H activation has emerged as a powerful approach to functionalize saturated cyclic amines. Our group recently disclosed a direct catalytic arylation reaction of piperidines at the α position to the nitrogen atom. 1-(Pyridin-2-yl)piperidine could be smoothly α-arylated if treated with an arylboronic ester in the presence of a catalytic amount of [Ru3(CO)12] and one equivalent of 3-ethyl-3-pentanol. A systematic study on the substrate and reagent scope of this transformation is disclosed in this paper. The effect of substitution on both the piperidine ring and the arylboronic ester has been investigated. Smaller (pyrrolidine) and larger (azepane) saturated ring systems, as well as benzoannulated derivatives, were found to be compatible substrates with the α-arylation protocol. The successful use of a variety of heteroarylboronic esters as coupling partners further proved the power of this direct functionalization method. Mechanistic studies have allowed for a better understanding of the catalytic cycle of this remarkable transformation featuring an unprecedented direct transmetalation on a RuII-H species. Copyright

THIENOPYRIDINE DERIVATIVES

The present invention provides a compound promoting osteogenesis. The present invention provides a compound having the following general formula (I) wherein R 1 is H or alkyl, R 2 is R a S-, R a O-, R a NH-, R a (R b )N- or cyclic amino, and R a and R b are alkyl which may be substituted, cycloalkyl which may be substituted, or the like, or a pharmacologically acceptable salt thereof.

PHARMACEUTICAL COMPOUNDS

Fused pyrimidines of formula (I); wherein A represents a thiophene or furan ring; n is 1 or 2; R1 is a group of formula (II); wherein m is 0 or 1; R30 is H or C1-C6 alkyl; R4 and R5 form, together with the N atom to which they are attached, a 5- or 6-membered saturated N-containing heterocyclic group which includes 0 or 1 additional heteroatoms selected from N, S and O, which may be fused to a benzene ring and which is unsubstituted or substituted; or one of R4 and R5 is alkyl and the other is a 5- or 6-membered saturated N-containing heterocyclic group as defined above or an alkyl group which is substituted by a 5- or 6-membered saturated N-containing heterocyclic group as defined above; R2 is selected from formula (a); wherein R6 and R7 form, together with the nitrogen atom to which they are attached, a morpholine, thiomorpholine, piperidine, piperazine, oxazepane or thiazepane group which is unsubstituted or substituted; and formula (b); wherein Y is a C2-C4 alkylene chain which contains, between constituent carbon atoms of the chain and/or at one or both ends of the chain, 1 or 2 heteroatoms selected from O, N and S, and which is unsubstituted or substituted; and R3 is an indazole group which is unsubstituted or substituted; and the pharmaceutically acceptable salt thereof have activity as inhibitors of P13K and may thus be used to treat diseases and disorders arising from abnormal cell growth, function or behaviour associated with P13 kinase such as cancer, immune disorders, cardiovascular disease, viral infection, inflammation, metabolism/endocrine disorders and neurological disorders. Processes for synthesizing the compounds are also described.